Sirois Jay E
Consumer Healthcare Products Association, 1625 Eye Street, NW, Suite 600 Washington, DC, 20006, USA.
Regul Toxicol Pharmacol. 2021 Jul;123:104944. doi: 10.1016/j.yrtph.2021.104944. Epub 2021 Apr 30.
In 2019, the California Office of Environmental Health Hazard Assessment initiated a review of the carcinogenic hazard potential of acetaminophen under Proposition 65. In conjunction with this review, a multidisciplinary team of experts with significant experience in the fields of hazard assessment, acetaminophen mechanism of action, epidemiology, and preclinical and clinical safety performed comprehensive weight of evidence reviews. The reviews evaluate multiple sources of data, including results from preclinical carcinogenicity, genotoxicity, human epidemiology, and mechanistic studies examining biochemical pathways of acetaminophen metabolism. This introductory article summarizes the comprehensive weight of evidence reviews that were performed on the carcinogenicity hazard potential of acetaminophen which are contained in 6 separate companion articles in this issue of Regulatory Toxicology & Pharmacology. Collectively, these results confirm that acetaminophen is not a carcinogenic hazard at any dose level, consistent with previous conclusions of key scientific bodies.
2019年，加利福尼亚州环境健康危害评估办公室根据第65号提案启动了对乙酰氨基酚致癌危害潜力的审查。在此审查过程中，一个由在危害评估、乙酰氨基酚作用机制、流行病学以及临床前和临床安全性领域具有丰富经验的专家组成的多学科团队进行了全面的证据权重审查。这些审查评估了多个数据来源，包括临床前致癌性、遗传毒性、人类流行病学的结果，以及研究乙酰氨基酚代谢生化途径的机制研究结果。这篇介绍性文章总结了对乙酰氨基酚致癌危害潜力进行的全面证据权重审查，这些审查包含在本期《监管毒理学与药理学》的6篇单独的配套文章中。总体而言，这些结果证实，乙酰氨基酚在任何剂量水平下都不存在致癌危害，这与关键科学机构之前的结论一致。
